Loading company…
MucoVax develops mucosal vaccines, including a candidate for genital herpes.
Founded in 1998 and based in Leiden, Netherlands, MucoVax develops mucosal vaccines. Its lead product is a vaccine candidate for genital herpes (HSV-2). The company raised EUR 3.1 million from Inventages Venture Capital on November 26, 2003.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in